Ortin Global

₹14.11As of Sun 8 Nov 2026, 12:00 UTC

NSE:ORTINGLOBEHealthcare

Country India

PE (Fwd) —

TSR 10Y CAGR (11.88%)

Div yield —

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.57

PE TTM —

TSR TTM 25.42%

Mkt cap ₹109.8M

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹16

10.60%

(93.73%)

Price above Reference Value

FY23

FY24

FY25

FY26

Earnings per share₹

(0.12)

(9.89)

(1.04)

(0.91)

75.51%

(8141.67%)

89.48%

12.52%

Revenue₹M

60.34

22.26

3.425

1.084

(26.69%)

(63.11%)

(84.61%)

(68.35%)

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

5Y

10Y

Peers

1.084

Revenue₹M

—

—

—

—

—

82.31

60.34

22.26

3.425

1.084

0.677

(66.12%)

(66.12%)

0

(68.35)

Revenue growth%

—

—

—

—

—

—

(26.69)

(63.11)

(84.61)

(68.35)

(37.51)

(65.73)

—

6

8.30

Gross margin%

—

—

—

—

—

42.37

42.30

(69.32)

32.70

8.30

8.30

32.70

32.70

5

(948.15)

Operating margin%

—

—

—

—

—

3.88

4.72

(201.30)

(162.34)

(948.15)

(100.00)

(162.34)

(162.34)

9

(683.03)

Net margin%

—

—

—

—

—

(4.84)

(1.55)

(361.21)

(247.12)

(683.03)

(100.00)

(247.12)

(247.12)

—

—

P/E ratio (avg)x

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

EV/EBITx

—

—

—

—

—

84.85

64.90

—

—

—

—

74.88

—

—

—

FCF yield (avg)%

—

—

—

—

—

—

—

—

—

—

—

—

—

86

—

FCF margin%

—

—

—

—

—

—

—

—

—

—

—

—

—

22

—

FCF / Net incomex

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

ROIC%

—

—

—

—

—

—

—

—

—

—

—

—

—

28

—

Return on equity%

—

—

—

—

—

—

—

—

—

—

—

—

—

73

—

Return on assets%

—

—

—

—

—

—

—

—

—

—

—

—

—

68

(0.91)

EPS₹

—

—

—

—

—

(0.49)

(0.12)

(9.89)

(1.04)

(0.91)

(0.08)

—

—

—

12.52

EPS growth%

—

—

—

—

—

—

75.51

(8140.70)

89.47

12.52

90.85

44.02

—

—

—

Bookvalue per sh₹

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

FCF per share₹

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Dividend per sh₹

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Div yield (avg)%

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Payout ratio%

—

—

—

—

—

—

—

—

—

—

—

—

—

—

8.131

Shares (diluted)M

—

—

—

—

—

8.137

7.800

8.131

8.131

8.131

◌8.131

(0.02%)

(0.02%)

83

—

Buyback yield%

—

—

—

—

—

—

4.14

(4.25)

—

—

◌—

—

—

83

—

D/E ratiox

—

—

—

—

—

—

—

—

—

—

—

—

—

7

114.7

Enterprise value₹M

—

—

—

—

—

270.7

184.8

175.2

161.0

112.8

114.7

(19.65%)

(19.65%)

12

—

LT debt₹M

—

—

—

—

—

—

—

—

—

—

—

—

—

17

Peers (US$1.124M)

Cap (US$)

PE

Mangalam Drugs…

4.954M

—

Vivimed Labs Limited

4.777M

—

Lasa Supergenerics…

2.369M

—

CordovaCann Corp.

1.096M

—

Capital

TTM

5Y

10Y

Leveragex

—

—

—

EBIT/Intx

(1,713)

(9.683)

(9.683)

Own earn%

—

—

—

Sh yield%

—

—

—

Owners

Insiders/Inst%

19.68

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/5

Revenue growth years

0/4

EPS growth years

3/4

Dividend streakyrs

0

Op margin range%

−948–5

$1 testx

—

Incr. ROIC%

—

Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹1.084M

(66.12%)

1.00×

Cost of revenue

₹0.994M

(61.95%)

1.59×

Operating expenses

₹10.37M

(24.37%)

24.85×

Revenue by region

No breakdown available

Reinvestment returns

No breakdown available